Episode 200: Gilead's growing pains, Covid's origins, & Theranos as prestige TV
Can biotech companies age gracefully? Where did Covid-19 come from? And does Theranos make for good television? We cover all that and more this week. We examine Gilead Sciences' recent struggles and ...
10 Mar 202231min
Episode 199: Biden's plans for Covid pills, the latest vaccine data, & fighting about CRISPR
Is "test to treat" too good to be true? Does it really matter who gets credit for CRISPR? And what's the offramp for Covid-19? We cover all that and more this week. Physician and researcher Kavita P...
3 Mar 202230min
Episode 198: Medical racism, new Covid vaccines, & the resilience of Regeneron
How many Covid-19 vaccines does the world really need? What will it take to address inequality in American health care? And should people be nicer to Moderna? First, we discuss the latest news in Cov...
24 Feb 202230min
Episode 197: Robert Califf's FDA return, the future of CRISPR, & another vaccine delay
Will there be a new ALS drug this year? What business does Wall Street have with CRISPR? And when can kids get Covid-19 vaccines? We cover all that and more this week. First, STAT's Nicholas Florko j...
17 Feb 202235min
Episode 196: Eric Lander's resignation, FDA's about-face, & Pfizer's lucrative pandemic
Does Big Science have a bullying problem? Why did the FDA change its tune on China? And what's cooler than $100 billion? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech pod...
10 Feb 202234min
Episode 195: Califf's sudden jeopardy, the quest for a PCSK9 pill, & Covid vaccines for kids
Does President Biden care about the FDA? What can aerobics instructors teach us about genetics? And when can kids get Covid-19 vaccines? STAT Washington correspondent Nicholas Florko joins us to chat...
3 Feb 202233min
Episode 194: Janet Woodcock on Covid antibodies, vaccines for kids, and responding to Omicron
Who gets to be an "expert" on Covid-19? Are Americans entitled to drugs that don't work? And how does the FDA deal with states' rights? First, we discuss the FDA's decision to halt the use of two Cov...
27 Jan 202225min
Episode 193: Jared Holz on Biotech's red tape, plus the latest billionaire science project
With biotech in the dumps, we talk to Oppenheimer analyst Jared Holz about why the world has soured on the sector and what it means for the future of medicine. Then, STAT’s Matthew Herper joins us to ...
20 Jan 202233min
